^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    NCR3LG1 underexpression + TMB-L

    i
    Other names: TMB | Tumor Mutational Burden, NCR3LG1, Natural Killer Cell Cytotoxicity Receptor 3 Ligand 1, B7-H6, DKFZp686O24166, B7 Homolog 6, Natural Cytotoxicity Triggering Receptor 3 Ligand 1, B7H6, Putative Ig-Like Domain-Containing Protein DKFZp686O24166/DKFZp686I21167
    Entrez ID:
    374383
    Related biomarkers:
    Expression
    Others
    over1year
    Correlation of low B7-H6 expression with efficacy of immunotherapy inpatients with melanoma. (ASCO 2023)
    The low B7-H6 expression was correlated with better efficacy immunotherapy. The effect of B7-H6 expression on immunotherapy needs to be further prospective trial validation.
    Clinical • PD(L)-1 Biomarker • IO biomarker
    |
    TMB (Tumor Mutational Burden) • NCR3LG1 (Natural Killer Cell Cytotoxicity Receptor 3 Ligand 1)
    |
    TMB-H • TMB-L • NCR3LG1 underexpression • NCR3LG1 underexpression + TMB-L